Literature DB >> 7591257

EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor.

K Ida1, S Kobayashi, T Taki, R Hanada, F Bessho, S Yamamori, T Sugimoto, M Ohki, Y Hayashi.   

Abstract

The t(11;22)(q24;q12) and t(21;22)(q22;q12) are specific chromosomal translocations found in the Ewing family of tumors including ES, PNET and Askin tumors. In these translocations, the amino-terminal portion of the EWS gene located in 22q12 fuses to the carboxyl-terminal portion of the FLI-1 gene located in 11q24 or the ERG gene located in 21q22, which belong to the ets oncogene superfamily of transcription activators. We investigated the chimeric mRNAs of 15 ESs (7 cell lines and 8 tumor samples) and 7 PNETs (3 cell lines and 4 tumor samples) using the RT-PCR method and sequencing. We detected 2 types of EWS-ERG chimeric mRNA in 2 ES cell lines and 1 PNET tumor sample in addition to 4 types of EWS-FLI-1 chimeric mRNA in 11 ESs (4 cell lines and 7 tumor samples) and 4 PNETs (2 cell lines and 2 tumor samples). There seemed to be no association between the type of chimeric mRNA and clinical features such as sex, age, primary site and histopathology of the patients. All of the chimeric mRNAs are generated from in-frame junctions and are thought to encode fusion proteins that may be the molecular mechanism involved in the Ewing family of tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591257     DOI: 10.1002/ijc.2910630407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  A method for accurate detection of translocation junctions in Ewing family of tumors.

Authors:  T Morishita; M E Bolander; K Zhang; S Tamai; Y Mii; G Sarkar
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

Review 2.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

3.  Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years.

Authors:  Gabriella Gamberi; Stefania Cocchi; Stefania Benini; Giovanna Magagnoli; Luca Morandi; Jennifer Kreshak; Marco Gambarotti; Piero Picci; Licciana Zanella; Marco Alberghini
Journal:  J Mol Diagn       Date:  2011-03-31       Impact factor: 5.568

4.  Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Authors:  Andrea Lunardi; Shohreh Varmeh; Ming Chen; Riccardo Taulli; Jlenia Guarnerio; Ugo Ala; Nina Seitzer; Tomoki Ishikawa; Brett S Carver; Robin M Hobbs; Valentina Quarantotti; Christopher Ng; Alice H Berger; Caterina Nardella; Laura Poliseno; Rodolfo Montironi; Mireia Castillo-Martin; Carlos Cordon-Cardo; Sabina Signoretti; Pier Paolo Pandolfi
Journal:  Cancer Discov       Date:  2015-02-04       Impact factor: 39.397

5.  Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells.

Authors:  H W Sohn; E Y Choi; S H Kim; I S Lee; D H Chung; U A Sung; D H Hwang; S S Cho; B H Jun; J J Jang; J G Chi; S H Park
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

6.  ETS-1-mediated transcriptional up-regulation of CD44 is required for sphingosine-1-phosphate receptor subtype 3-stimulated chemotaxis.

Authors:  Wenliang Zhang; Jiawei Zhao; Jen-Fu Lee; Allison Gartung; Hiba Jawadi; Wanyu Louis Lambiv; Kenneth V Honn; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

7.  Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF.

Authors:  Thomas R Johnson; Sweaty Koul; Binod Kumar; Lakshmipathi Khandrika; Sarah Venezia; Paul D Maroni; Randall B Meacham; Hari K Koul
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

8.  Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Authors:  Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wilfred F J van Ijcken; Wytske M van Weerden; Guido Jenster
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

Review 9.  Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Authors:  Federica Recine; Alberto Bongiovanni; Nada Riva; Valentina Fausti; Alessandro De Vita; Laura Mercatali; Chiara Liverani; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2017-02-23       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.